Christine McMahon, MD

Professional Titles

• Assistant Professor of Medicine

Research Interests

Dr. McMahon is focused on clinical trials and translational studies for AML and MDS. Her previous research has focused on mechanisms of response and resistance to FLT3 inhibitors in acute myeloid leukemia.

Publications

• Gil KB, Borg J, Pereira RM, Inguva-Sheth A, Araujo G, Rahkola J, Showers W, Grier A, D'Alessandro A, Smith C, McMahon C, Pollyea DA, Gillen AE, Amaya ML. The STAT3-VDAC1 axis modulates mitochondrial function and plays a critical role in the survival of acute myeloid leukemia cells. Haematologica. 2026 Feb 1;111(2):481-492. PubMed PMID: 40534505
• McMahon C, Raddi MG, Mohan S, Santini V. New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes. Am Soc Clin Oncol Educ Book. 2025 Jun;45(3):e473654. PubMed PMID: 40334184
• Lachowiez CA, Heiblig M, Aspas Requena G, Tavernier-Tardy E, Dai F, Ashango AB, Peters DT, Fang J, Kaempf A, Long N, Eide CA, Kurtz SE, Xie W, Agarwal A, Sahasrabudhe A, McMahon CM, Amaya ML, Meyers G, Gandhi A, Leonard J, Hayes-Lattin B, Maziarz RT, Traer E, Cook RJ, Swords R, Braun TP, Saultz JN, Eckel AM, Loken MR, Zeidner JF, Tyner JW, Pollyea DA. Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study. Blood Cancer Discov. 2025 Sep 3;6(5):437-449. PubMed PMID: 40396900
• Arellano ML, Thirman MJ, DiPersio JF, Heiblig M, Stein EM, Schuh AC, Žucenka A, de Botton S, Grove CS, Mannis GN, Papayannidis C, Perl AE, Issa GC, Aldoss I, Bajel A, Dickens DS, Kühn MWM, Mantzaris I, Raffoux E, Traer E, Amitai I, Döhner H, Greco C, Kovacsovics T, McMahon CM, Montesinos P, Pigneux A, Shami PJ, Stone RM, Wolach O, Harpel JG, Chudnovsky Y, Yu L, Bagley RG, Smith AR, Blachly JS. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood. 2025 Aug 28;146(9):1065-1077. PubMed PMID: 40332046
• McMahon CM. Beyond conVENtional 7 3 in acute myeloid leukemia. Blood. 2025 Apr 24;145(17):1831-1832. PubMed PMID: 40272856
• Santos J, Abbott D, Bosma G, Kent A, Schwartz M, McMahon CM, Gutman J, Pollyea DA, Amaya ML. Comparison of treatment-related and de novo CCUS: a retrospective analysis from two centers. Leuk Lymphoma. 2025 Aug;66(8):1543-1545. PubMed PMID: 40080662
• Kent A, Gil KB, Jones MK, Linden B, Purev E, Haverkos B, Schwartz M, McMahon C, Amaya M, Smith CA, Bosma G, Abbott D, Rabinovitch R, Milgrom SA, Pollyea DA, Gutman JA. Outcomes of Haplo-Cord Versus Dual Cord Transplants: A Single-Center Retrospective Analysis. Transplant Cell Ther. 2025 Apr;31(4):267.e1-267.e11. PubMed PMID: 39154914
• Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, Mannis GN, Perl A, Dickens DS, McMahon CM, Traer E, Zwaan CM, Grove CS, Stone R, Shami PJ, Mantzaris I, Greenwood M, Shukla N, Cuglievan B, Kovacsovics T, Gu Y, Bagley RG, Madigan K, Chudnovsky Y, Nguyen HV, McNeer N, Stein EM. Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). J Clin Oncol. 2025 Jan;43(1):75-84. PubMed PMID: 39121437
• Peters DT, Nicolet D, Madanat YF, Gonzalez-Lugo J, Ambinder A, Chan O, Foucar CE, Sahasrabudhe KD, Ameyi J, Mrózek K, Lin T, Al-Ali N, Lancet J, Barredo B, Banaszak LG, Hochman MJ, Ragon BK, McMahon CM, Haque T, Mims AS, Eisfeld AK, Zeidner JF. Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium. Br J Haematol. 2025 Dec 3. [Epub ahead of print] PubMed PMID: 41332326
• Nadorp B, Lasry A, Loghavi S, Patel R, Mansour H, Kelly BJ, Walker CJ, Buss J, Boateng I, Al-Santli W, Ciantra Z, Austin R, Heyrosa A, Desai H, Laganson A, Abaza H, Procell L, Patel T, Kaffenberger B, Wijeratne S, Guillamot M, Velegraki M, Chiriboga L, Li Z, Abruzzo LV, Pollyea DA, McMahon C, Shana'ah A, Byrd JC, Shih A, Levine RL, Papapetrou EP, Tsirigos A, Mardis ER, Mims AS, Aifantis I, Eisfeld AK. Multiomic characterization, early detection, and therapeutic targeting of myeloid sarcoma. bioRxiv. 2025 Dec 5. PubMed PMID: 41573880
• Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, Mannis GN, Perl A, Dickens DS, McMahon CM, Traer E, Zwaan CM, Grove CS, Stone R, Shami PJ, Mantzaris I, Greenwood M, Shukla N, Cuglievan B, Kovacsovics T, Gu Y, Bagley RG, Madigan K, Chudnovsky Y, Nguyen HV, McNeer N, Stein EM. Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). J Clin Oncol. 2025 Jan;43(1):75-84. PubMed PMID: 39121437
• Pollyea DA, Stevens BM, Abbott D, Amaya M, Gutman JA, Kent A, McMahon C, Schwartz M, Smith C, Dell-Martin J, Sohalski C, Ellis A, Haag M, Schowinsky J, Pan Z, Patel SB, Ransom M, Gillen A, Jordan CT, Pietras EM. Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trial. EClinicalMedicine. 2025 Nov;89:103546. PubMed PMID: 41140451
• Duarte C, Abbot D, Bosma G, Kent A, Schwartz M, Collins C, Angelos MG, McMahon C, Gutman J, Pollyea DA, Amaya M. Impact of demographic factors on clinical outcomes of patients with acute myeloid leukemia. Haematologica. 2025 Sep 11. [Epub ahead of print] PubMed PMID: 40931864
• Gilbert JS, Connor M, Bosma G, Zhang J, McMahon CM, Amaya ML, Gutman J, Schwartz M, Kent A, Abbott D, Pollyea DA. Known Prognostic Models Fail to Predict Outcomes for Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Retrospective Analysis. Am J Hematol. 2025 Nov;100(11):2140-2143. PubMed PMID: 40810378
• Fang J, Bosma G, Aisner D, McMahon C, Amaya M, Schwartz M, Kaiser J, Abbott D, Pan Z, Schowinsky J, Pang C, Gutman JA, Pollyea DA. White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia. Leuk Lymphoma. 2024 Jun;65(6):800-807. PubMed PMID: 38814858
• Abaza Y*, McMahon C*, Garcia JS. Advancements and Challenges in the Treatment of AML. Am Soc Clin Oncol Educ Book. 2024 Apr;44(3):e438662. PubMed PMID: 38662975
• Lachowiez CA, Ravikumar VI, Othman J, O'Nions J, Peters DT, McMahon C, Swords R, Cook R, Saultz JN, Tyner JW, Dillon R, Zeidner JF, Pollyea DA. Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML. Blood. 2024 Dec 26;144(26):2788-2792. PubMed PMID: 39486083
• Gil KB, Abbott D, Amaya ML, Schwartz M, Gutman JA, Kent A, Bosma G, Pollyea DA, McMahon CM. Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia. Leuk Lymphoma. 2024 Dec;65(14):2228-2230. PubMed PMID: 39229898
• Kent A, Gil KB, Jones MK, Linden B, Purev E, Haverkos B, Schwartz M, McMahon C, Amaya M, Smith CA, Bosma G, Abbott D, Rabinovitch R, Milgrom SA, Pollyea DA, Gutman JA. Outcomes of Haplo-Cord Versus Dual Cord Transplants: A Single-Center Retrospective Analysis. Transplant Cell Ther. 2024 Aug 17. [Epub ahead of print] PubMed PMID: 39154914
• Pei S, Shelton IT, Gillen AE, Stevens BM, Gasparetto M, Wang Y, Liu L, Liu J, Brunetti TM, Engel K, Staggs S, Showers W, Sheth AI, Amaya ML, Minhajuddin M, Winters A, Patel SB, Tolison H, Krug AE, Young TN, Schowinsky J, McMahon CM, Smith CA, Pollyea DA, Jordan CT. A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy. Cancer Discov. 2023 Sep 6;13(9):2032-2049. PubMed PMID: 37358260
• Gurule NJ, Malcolm KC, Harris C, Knapp JR, O'Connor BP, McClendon J, Janssen WJ, Lee FFY, Price C, Osaghae-Nosa J, Wheeler EA, McMahon CM, Pietras EM, Pollyea DA, Alper S. Myelodysplastic neoplasm-associated U2AF1 mutations induce host defense defects by compromising neutrophil chemotaxis. Leukemia. 2023 Oct;37(10):2115-2124. PubMed PMID: 37591942
• Kent A, Schwartz M, McMahon C, Amaya M, Smith CA, Tobin J, Marciano K, Rezac R, Bosma G, Pollyea DA, Gutman JA. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse. Bone Marrow Transplant. 2023 Aug;58(8):849-854. PubMed PMID: 37185614
• Gutman JA, Winters A, Kent A, Amaya M, McMahon C, Smith C, Jordan CT, Stevens B, Minhajuddin M, Pei S, Schowinsky J, Tobin J, O'Brien K, Falco A, Taylor E, Brecl C, Zhou K, Ho P, Sohalski C, Dell-Martin J, Ondracek O, Abbott D, Pollyea DA. Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia. Haematologica. 2023 Oct 1;108(10):2616-2625. PubMed PMID: 37051756
• Pollyea DA, Winters A, McMahon C, Schwartz M, Jordan CT, Rabinovitch R, Abbott D, Smith CA, Gutman JA. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Bone Marrow Transplant. 2022 Feb;57(2):160-166. PubMed PMID: 34645926
• Abbott D, Cherry E, Amaya M, McMahon C, Schwartz M, Winters A, Schowinsky J, Jordan CT, Smith C, Gutman JA, Pollyea DA. The propriety of upgrading responses to venetoclax-azacitidine in newly diagnosed patients with acute myeloid leukemia. Leuk Lymphoma. 2021 Jun;62(6):1466-1473. PubMed PMID: 33375853
• Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, Sato A, Schowinsky J, Inguva A, Minhajuddin M, Pei S, Stevens B, Winters A, Jordan CT, Smith C, Gutman JA, Pollyea DA. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021 Dec 28;5(24):5565-5573. PubMed PMID: 34610123
• Nelson ND, McMahon CM, El-Sharkawy Navarro F, Freyer CW, Roth JJ, Luger SM, Bagg A, Morrissette JJD. Rapid fluorescence in situ hybridisation optimises induction therapy for acute myeloid leukaemia. Br J Haematol. 2020 Dec;191(5):935-938. PubMed PMID: 33460058
• Stahl M, Shallis RM, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, Konig H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukherjee S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuña-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia. 2020 Dec;34(12):3149-3160. PubMed PMID: 32132655
• Shallis RM, Stahl M, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, Konig H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukhereje S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuña-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. Leuk Lymphoma. 2020 May;61(5):1220-1225. PubMed PMID: 32100599
• Abbott D, Cherry E, Amaya M, McMahon C, Schwartz M, Winters A, Schowinsky J, Jordan CT, Smith C, Gutman JA, Pollyea DA. The propriety of upgrading responses to venetoclax azacitidine in newly diagnosed patients with acute myeloid leukemia. Leuk Lymphoma. 2020 Dec 30:1-9. [Epub ahead of print] PubMed PMID: 33375853

Professional Memberships

• American Society of Hematology, Member
• American Society of Clinical Oncology, Member

Practice Locations

UCHealth Blood Disorders and Cell Therapies Center - Anschutz Medical Campus
1665 Aurora Court
3rd floor, Anschutz Cancer Pavilion
Aurora, CO 80045
720-848-6400

UCHealth Anschutz Inpatient Pavilion - Anschutz Medical Campus
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

Hospital Affiliation

• University of Colorado Hospital

Center Affiliations

• University of Colorado Cancer Center

Specialty Information

Specialties

• Hematology, Board Certification (2019, 2019)
• Medical Oncology, Board Certification (2018, 2018)
• Internal Medicine, Board Certification (2015, 2015)

Conditions & Treatments

• Cancers - Leukemia (Adult Acute)
• Cancers
• Cancers - Myelodysplastic Syndrome
• Cancers - Leukemia (Adult Chronic)